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Abstract
Background: Chronic heart failure is characterized by an inability of the heart to pump enough blood to meet the demands of
the body, resulting in the hallmark symptom of exercise intolerance. Chronic underperfusion of the peripheral tissues and impaired
nitric oxide bioavailability have been implicated as contributors to the decrease in exercise capacity in these patients. nitric oxide
bioavailability has been identified as an important mediator of exercise tolerance in healthy individuals, but there are limited
studies examining the effects in patients with chronic heart failure.
Objective: The proposed trial is designed to determine the effects of chronic inorganic nitrate supplementation on exercise
tolerance in both patients with heart failure preserved ejection fraction (HFpEF) and heart failure reduced ejection fraction (HFrEF)
and to determine whether there are any differential responses between the 2 cohorts. A secondary objective is to provide mechanistic
insights into the 2 heart failure groups’ exercise responses to the nitrate supplementation.
Methods: Patients with chronic heart failure (15=HFpEF and 15=HFrEF) aged 40 to 85 years will be recruited. Following an
initial screen cardiopulmonary exercise test, participants will be randomly allocated in a double-blind fashion to consume either
a nitrate-rich beetroot juice (16 mmol nitrate/day) or a nitrate-depleted placebo (for 5 days). Participants will continue daily dosing
until the completion of the 4 testing visits (maximal cardiopulmonary exercise test, submaximal exercise test with echocardiography,
vascular function assessment, and vastus lateralis muscle biopsy). There will then be a 2-week washout period after which the
participants will cross over to the other treatment and complete the same 4 testing visits.
Results: This study is funded by National Heart Foundation of Australia and Victoria University. Enrolment has commenced
and the data collection is expected to be completed in mid 2018. The initial results are expected to be submitted for publication
by the end of 2018.
Conclusions: If inorganic nitrate supplementation can improve exercise tolerance in patients with chronic heart failure, it has
the potential to aid in further refining the treatment of patients in this population.
Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12615000906550;
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368912 (Archived by WebCite at
http://www.webcitation.org/6xymLMiFK)
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Introduction
Background
Chronic heart failure (CHF) is a condition characterized by the
inability of the heart to pump sufficient blood to meet the
metabolic demands of the body. Affecting over 23 million
people worldwide, this disease is the leading cause for hospital
admission in both Europe and the United States [1]. CHF is a
multifarious syndrome that presents with different physiological
impairments depending on age, medical history, pathology, and
left ventricular ejection fraction status [2]. Although the etiology
of CHF may vary, patients are all plagued by the hallmark
symptoms of exercise intolerance (low aerobic capacity),
dyspnea, and fatigue [3].
Exercise intolerance, defined by a reduced peak oxygen uptake
(VO2peak), independently predicts morbidity and mortality and
directly contributes to a reduced quality of life in patients with
CHF [4-6]. In comparison with healthy controls, patients with
CHF have significantly lower VO2peak (~13.5ml/kg/min vs
~23.8ml/kg/min), with accompanying reductions in cardiac
output (CO) by 52-53% during maximal exercise [7-9].
Although it was historically assumed that this inability to
augment CO during exercise was the primary contributor to
exercise intolerance, more recent investigations suggest that
resulting under-perfusion of the peripheral muscular tissues
may have a more detrimental impact [3,10].
Following acute heart failure, there is an increased activation
of the sympathetic nervous system (SNS), which leads to
vasoconstriction of arteries supplying blood to the peripheral
tissues to defend central blood pressure and vital organ perfusion
[10]. Although this SNS response is critical initially, continued
overactivation results in chronic underperfusion of the skeletal
muscle tissues, thereby contributing to capillary density
rarefaction and a preferential loss of type-I oxidative fibers, and
thus shifting these patients to a more glycolytic phenotype
[11-14]. In the heart and skeletal muscles, there are significant
abnormalities in the mitochondrial function, leading to decreases
in oxidative phosphorylation [15]. Within the vasculature, a
reduction in nitric oxide (NO) bioavailability is also highly
prevalent in CHF and has been correlated with both the severity
of CHF and the patients’ functional capacity [16]. NO is a key
regulator of blood flow and as large and small vessel
vasodilation is a crucial contributor to exercise capacity, the
inability of patients with CHF to up-regulate NO could be a
limiting factor in their exercise tolerance [3,17]. This knowledge
has brought about a fundamental shift in the treatment focus for
CHF, whereby interventions are now targeting improvements
within the peripheral tissue function to restore exercise tolerance.
One emerging therapeutic approach is supplementing with
dietary inorganic nitrate (found in kale, green leafy vegetables,
or beetroot juice [BTR]) to increase circulating NO
bioavailability [18]. This occurs via a 2-step process, whereby
nitrate is swallowed and absorbed via the gut and released into
circulation. Approximately 25% of nitrate becomes highly
concentrated in the salivary glands, which is then secreted and
subsequently reduced via oral commensal bacteria to nitrite,
which is then swallowed and absorbed into the circulation [19].
The circulating nitrite in the plasma may act as a relatively
protected NO species that can be reduced to NO in low-oxygen
environments (such as in tissues with low partial pressure of
oxygen or during exercise).
Studies in healthy populations have demonstrated a myriad of
benefits in exercise performance following nitrate
supplementation, including increases in time to exhaustion,
oxygen consumption efficiency (during submaximal exercise),
total power output, and decreased systemic blood pressure
[20-27]. Inorganic nitrate supplementation has even greater
potential efficacy in clinical populations as supplementation
may be an effective way of assisting in the targeted redistribution
of blood flow in the underperfused peripheral tissues [18].
However, in contrast to the numerous studies in healthy
populations, there are relatively few studies to date that have
examined the effects of inorganic nitrate supplementation on
exercise capacity in clinical patients, and only 4 have been on
the CHF population [28-31]. A further limitation in our current
understanding of inorganic nitrate supplementation in patients
with CHF is the lack of substantial evidence in each of the 2
individual classifications of CHF, with a large proportion of the
publications focusing only on one classification.
Currently, there are 2 classifications for patients with heart
failure differentiated by whether the patient has a preserved
ejection fraction (HFpEF, also known as diastolic dysfunction)
or a reduced ejection fraction (HFrEF, also known as systolic
dysfunction). HFrEF often results from an acute ischemic event
that causes tissue death, leaving the cardiac muscle less able to
contract adequately. In these patients, the ejection fraction is
reduced because of left ventricular chamber dilation [32,33].
Patients with HFrEF have a lower CO both at rest and during
exercise as compared with HFpEF patients and healthy controls
[8]. HFpEF typically has a slower onset and these patients are
more likely to be older, female, and suffer from a myriad of
other comorbidities. Although they also have significant left
ventricular remodeling, in HFpEF, the chamber size remains
unchanged, but there are increases in the wall thickness and the
ratio of ventricular mass to chamber volume. These
maladaptations lead to significant elevations in LV filling
pressures, which is known to cause exertional dyspnea and
further contribute to exercise intolerance [34]. Additionally, the
impaired arterial hemodynamic profile of these patients
(increased arterial stiffness, reduced exercise induced
vasodilation) creates a unique model for which a vasodilatory
intervention, such as inorganic nitrate supplementation, could
be very effective [35,36].
In CHF, the HFpEF cohort has been the most studied. Zamani
et al provided acute supplementation of inorganic nitrate in the
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form of beetroot juice (12.9 mmol nitrate) to 17 HFpEF patients
and saw improvements in total time to exhaustion (TTE) and
VO2peak during a maximal exercise test [29]. The performance
benefits were accompanied by an increase in CO, although this
was secondary to a decrease in systemic vascular resistance
[29]. Following chronic inorganic nitrate dosing, Eggebeen et
al found that 6.1 mmol nitrate/day for 7 days (in the form of
beetroot juice) led to a 24% increase in TTE during an exercise
bout of cycling at 75% of each individual’s maximum power
output [28]. Similarly, Zamani et al identified significant
increases in TTE following a 2-week potassium nitrate dosing
regimen (6 mmol/day for 1 week, increasing to 18 mmol/day
for the second week) [37]. These studies lend support to
inorganic nitrate supplementation’s potential efficacy for
improving exercise tolerance in patients with HFpEF; however,
the small sample sizes and limited mechanistic data leave plenty
of scope for future studies.
In comparison with the positive results seen in HFpEF cohorts,
data for HFrEF remains limited. A recent study by Hirai et al
supplemented HFrEF patients with 12.9 mmol nitrate/day in
the form of beetroot juice for 9 days and reported no changes
in any of the parameters examined, including exercise
performance, central hemodynamics, and blood pressure [31].
The authors suggest that the negative findings could be because
HFrEF patients have relatively normal oxygen extraction rates
within the peripheral tissues. Although Hirai et al is the only
human study examining the effects of inorganic nitrate
supplementation on exercise capacity in patients with HFrEF,
Coggan et al conducted a study examining the effects of nitrate
supplementation on isokinetic knee extensor power [30]. This
study showed a 13% increase in the maximal power output
following a single dose of inorganic nitrate (11.2 mmol). The
authors suggested that the substantial improvement (they note
that it is much larger than the 6% increase observed in healthy
controls) was due to NO’s known effect of increasing the
activation of cyclic guanosine monophosphate. As this activation
is known to lead to increases in maximal power output,
particularly in type II fibers, it lends further support to nitrate’s
efficacy in CHF (where patients are known to be more type
II-fiber dominant). In further support of these findings, 2
separate CHF rat model studies, 1 using an acute dose (5 mg/kg
sodium nitrite) and 1 using a chronic dose (1 mmol
nitrate/kg/day for 5 days), demonstrated significant increases
in blood flow and vascular conductance in skeletal muscle
[38,39]. The acute sodium nitrite infusion also showed a
preferential increase in blood flow, specifically in the muscles
of the rats with a higher percentage of both type IIb + IId/x
fast-twitch fibers [38]. This further illustrates the potential
efficacy of nitrate supplementation within the HFrEF population.
Thus, despite the lack of positive findings in the study by Hirai
et al, there remains a lot of promise in the use of nitrate
supplementation in patients with HFrEF.
Overall, the area of inorganic nitrate supplementation in patients
with CHF is relatively new. The current studies have small
sample sizes (3 of the 5 human studies had ≤12 participants)
that lack diversity in gender (Hirai et al only had male
participants) and testing modalities (all exercise studies used
cycle ergometry). Moreover, no study to date has sought to
examine and compare the effects of nitrate supplementation in
HFrEF and HFpEF patients within the same testing protocol.
The development of research trials recruiting both HFrEF and
HFpEF patients is critical to advancing our understanding of
how to best clinically target and treat the mechanistic differences
between these 2 distinct classes of CHF.
Objective
The primary aim of this study is to test the hypothesis that 5
days of inorganic nitrate supplementation (16 mmol/day) will
improve exercise tolerance (VO2peak and TTE) in both HFpEF
and HFrEF patients. We further hypothesize that patients with
HFpEF will have larger improvements in exercise tolerance
than patients with HFrEF because of greater impairments in
their peripheral muscular tissues. The secondary aim of the
project is to identify the mechanistic contributors to exercise
tolerance in both heart failure classifications via examining the
following outcome measures:
1. Gastrocnemius tissue oxygenation at rest and during
submaximal and maximal exercise via near-infrared
spectroscopy (NIRS)
2. Vastus lateralis muscle tissue composition and function
(angiogenesis, capillaries per unit area and per muscle fiber,
mitochondrial function, and muscle fiber composition)
3. Vascular function via brachial artery flow-mediated dilation,
lower-limb blood flow via plethysmography, and pulse
wave velocity (PWV) and reflection.
Methods
Study Design and Participants
This is a randomized, double-blind, placebo-controlled,
crossover study (see Figure 1). Following a screening visit,
participants will be randomized to consume either nitrate-rich
beetroot juice or a nitrate-depleted placebo for 5 days. Following
this 5-day loading, the participants will continue daily dosing
until the completion of the 4 testing visits (maximal
cardiopulmonary exercise test (CPX), submaximal exercise test
with echocardiography, vascular function assessment, and vastus
lateralis muscle biopsy). Due to the need for adequate rest days
between exercise visits, it could take up to 2 weeks in total to
complete all testing visits within each round. However, both
the dosing days and testing order will be matched within each
participant between the 2 rounds of supplementation.
Participants will then have a 2-week washout period before
completing the second round of the study.
Recruitment Strategies and Eligibility
We aim to recruit 15 patients with HFrEF and 15 patients with
HFpEF. A total sample of 30 is a realistic number of patients
that can be recruited within the time frame of the study (18
months) and is similar to other successful studies in this field
[29,40].
Recruitment will be open to individuals between the ages of 40
and 85 years who have diagnosed stable CHF with either HFrEF
≤40% or HFpEF ≥50% with no major changes in medications
for at least 3 months (see Textboxes 1 and 2).
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Figure 1. Max CPX: maximal cardiopulmonary exercise test; submaximal echo: submaximal exercise test with echocardiograph imaging; vascular
testing: resting measures of blood flow and arterial function; and muscle biopsy: vastus lateralis muscle biopsy.
Textbox 1. Inclusion criteria.
1. Aged between 40 and 85 years
2. Diagnosed stable chronic heart failure (CHF) with either reduced ejection fraction (HFrEF) ≤40% or preserved ejection fraction (HFpEF) ≥50%
3. New York Heart Association class II-III
4. On stable medications for at least 3 months
5. Peak VO2 <85% of age-predicted max
Additional criteria for HFpEF recruitment
1. Evidence of abnormal diastolic filling pressure (eg, abnormal E/e′, abnormal deceleration time, dilated left atrial volume, or elevated brain
natriuretic peptide [if available]) [41]
2. Signs and symptoms of heart failure, plus definite episodes of decompensated heart failure (adjudicated via Boston Criteria)
Textbox 2. Exclusion criteria.
1. A major cardiovascular event within the previous 6 weeks or a planned hospitalization within the next 2 months
2. Patients with an ejection fraction between 41 and 49
3. Uncontrolled diabetes (>9% HbA1C [glycated hemoglobin])—Can delay start of testing by 3 months until levels are controlled and stable
4. Foot ulcers/advanced neuropathy or other musculoskeletal condition that could limit exercise performance
5. Abnormal response to CPX
6. Allergy to beets or proton pump inhibitors
7. Refusal or inability to abstain from the use of proton pump inhibitors for 24 hours before testing
Potential participants will be identified through medical chart
reviews and will be contacted in person during a hospital or
clinic visit. They will be given the contact information for the
trial recruitment coordinator and instructed to contact the team
if they wish to learn more about the study. At all stages, potential
participants will be reminded that their participation in the study
is voluntary and that their decision to participate or not will in
no way affect their usual care.
Screening Visit
Patients who wish to participate in the study will be asked to
sign an informed consent. They will then complete a screening
maximal CPX that will be supervised by a medical practitioner.
Although the primary purpose of CPX is to screen for adverse
events or contraindications to participation in the study, it will
also serve as a familiarization visit for the participants. This
CPX employs a 2-step protocol that includes 6 min of
low-intensity walking at 1.4 km/hour at a 4% grade. Following
this, the speed and/or incline will be increased in an
individualized manner as the participants’ capabilities allow
until maximal exertion is achieved. The test will only be stopped
if the medical practitioner deems it unsafe to continue or the
patient requests to stop. The max CPX protocol will be kept
constant between visits for each individual subject. Similar
protocols have been previously used in this population as the
2-step protocol allows for collection of both submaximal and
maximal measures of aerobic capacity and function within 1
exercise bout [42-44].
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Supplementation
Following successful completion of the screening CPX,
participants who meet the inclusion criteria will be randomly
allocated in a double-blind fashion to determine the order of
treatment (beetroot juice or placebo). A technical staff member
of Victoria University, external to the project, will color code
the beetroot juice bottles and provide a randomization sheet to
the research team that has the conditions removed and replaced
with colors.
Participants will consume three 70-ml bottles of beetroot juice
(BEET IT shot, James White Drinks, Ipswich, UK) per day of
either a nitrate-rich beetroot juice (16 mmol of nitrate/day total)
or a nitrate-depleted placebo for 5 days before they commence
testing. They will then continuously dose until they complete
all 4 testing visits. There will be a 2-week washout period
between the 2 rounds. As the half-life of nitrate is 5-8 hours, a
2-week washout period should be sufficient to minimize any
possible residual effect of nitrate [45]. The order of testing visits
will be kept consistent for each participant between the beetroot
juice and placebo testing rounds. On testing days, patients will
consume the first bottle of either beetroot juice or placebo 2.5
to 3 hours prior, as plasma nitrite concentration peaks within
2.5 to 3 hours postingestion [23,24]. To assess supplementation
compliance, participants will maintain a dosing log and return
all bottle caps to the research team.
The cumulative body of literature identifies that decreases in
the oxygen cost of exercise and increases in power output and
time to exhaustion were seen in studies using a minimum dose
of 5.2 mmol nitrate for 6 days [22,25-27]. A longer dosing
protocol (15 days) demonstrated that improvements in
steady-state VO2 seen at day 5 were maintained but not increased
at day 15 [46]. A previous clinical trial has demonstrated that
an 18.1 mmol nitrate/day dose was feasible and safe for patients
with peripheral arterial disease, whereas doses as high as 12.9
mmol nitrate/day have been used in the CHF population
[40,47,48]. Thus, the dosing amount (16 mmol nitrate) and
duration (minimum of 5 days before first testing session) for
this study were selected to maximize the potential effects of the
nitrate supplementation.
Quality of Life and Health Status Questionnaires
In addition to the physiological measures attained, participants
will be asked to complete a series of questionnaires through the
study, including the Minnesota Living with Heart Failure
Questionnaire (MLHFQ) to determine how their CHF has
affected their life during the last month; the Subjective Exercise
Experience Scale (SEES) to assess the effect of an acute exercise
bout on positive well-being, psychological distress, and fatigue;
and finally, they will complete a Physical Activity Questionnaire
(PAQ) to confirm their current level of physical activity [49,50].
Participants will be asked to complete MLHFQ and PAQ a total
of 2 times, once before commencing each testing round to ensure
there is no change in how their CHF affects their daily life and
how much they are exercising. MLHFQ has been previously
validated for the use of the resulting physical, emotional, and
total scores in patients with CHF [50]. Participants will be asked
to complete SEES after every exercise test for the duration of
the study, including the screening CPX. This 12-question scale
was developed and validated as a 3-factor measure (positive
well-being, psychological distress, and fatigue) of psychological
response to exercise and has been previously validated [51].
Maximal Cardiopulmonary Exercise Test Testing Visit
Participants will complete a 2-phase treadmill test identical to
the screening CPX but with the addition of blood draws at rest
and 10 min into recovery (to allow for postexercise blood
volume stabilization) to quantify both resting plasma
nitrate/nitrite as well as postexercise nitrate/nitrite changes.
Upon arrival for the testing visit, a catheter will be inserted into
the antecubital vein of the participant to allow for repeated blood
sampling. At this visit, 30 ml of blood will be collected in total.
Following the resting blood draw, participants will be fitted
with a 12-lead electrocardiograph to monitor their heart rhythms
throughout the maximal test. Additionally, a near-infrared
spectrometry (NIRS, PortaMon, Artinis Medical Systems B.V.,
The Netherlands) device will be placed on the skin above the
gastrocnemius muscle of the participant. The NIRS system is
noninvasive and provides an assessment of tissue oxygenation
via the transmission of specific wavelengths of light (850 nm
and 764 nm) that are absorbed by oxy- and deoxyhemoglobin,
respectively [52]. A detection probe within the device measures
the intensity of the received and transmitted light, which is
communicated to a laptop via Bluetooth, and the corresponding
software calculates the relative concentrations (and relative
change) of oxygenated and deoxygenated hemoglobin within
the muscle tissue. The device will be placed on the widest part
of the medial head of the gastrocnemius, which is located by
having the participant perform a short series of calf raises. A
measuring tape will be used to identify the vertical point on the
calf corresponding to the widest girth. A skinfold measurement
will be taken at the selected site to ensure that the adipose tissue
is less than 1.5 cm (typically the calf has less than 1 cm) [53].
The site will then be prepped with alcohol wipes (and shaving
if appropriate), and the device will be affixed with micropore
tape. Once the device is placed, vertical measurements are then
taken from the top of the device to the bottom of the medial
malleolus for reproducibility purposes on future tests. To ensure
no light enters the NIRS device, a black plastic will be wrapped
over the device and taped into place.
Additionally, a PhysioFlow (Physio Flow; Manatec Biomedical;
Macheren, France) device will be used to estimate CO and the
systemic vascular resistance index both at rest and during
exercise. The device is a noninvasive hemodynamic monitor
that provides real-time calculations of CO and various other
parameters based on the morphological analysis of the
bioelectrical impedance waveform. This device has been
previously validated for measures of CO in healthy populations,
but the studies in clinical populations thus far have been limited
[54-57].
After 10 min of resting data collection, participants will be asked
to complete a 2-step maximal treadmill CPX (as in the screening
visit). Upon completion, the participant will be seated for
recovery and at 10-min postcompletion will have a final 5 ml
of blood drawn. Additionally, to allow for comparisons of the
NIRS results to be made between subjects, a postexercise
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physiological calibration will be used to convert the relative
concentration values to a normalized scale. For this, an occlusion
cuff will be applied to the NIRS leg just above the knee, and
the patients will undergo 5 min of ischemia. The baseline value
for the scale will be the plateau of the oxygenated hemoglobin
signal, whereas the signal response to postcuff release will
provide a functional maximum for the normalized scale. All
values obtained during the testing will then be expressed as a
percentage value within these ranges [58].
Vascular Function Visit
Patients will be asked to fast overnight and to abstain from
exercise for the 24 hours prior and to avoid caffeine and smoking
for the 3 hours before testing. They will also be asked to hold
their morning medications until immediately post-testing. All
vascular testing will occur following a minimum of 10 min,
with the participant in the supine position.
Brachial artery flow-mediated dilation (FMD) will be obtained
using a high-resolution Terason ultrasound (LifeHealthcare,
New South Whales, Australia) to capture images of the brachial
artery. This method has been previously used in clinical
populations and has been shown to be reliable [40,59,60]. In
brief, FMD will be assessed at baseline, following 5 min of
forearm occlusion, and 2 min following occlusion cuff release
(reactive hyperemia). These data points will be used to calculate
the percentage of change in brachial artery diameter following
reactive hyperemia.
Lower limb blood flow will be assessed via venous occlusion
strain gauge plethysmography both at rest and during reactive
hyperemia following 5 min of occlusion via Hokanson A16 (DE
Hokanson, Bellevue, WA), as was previously described [61,62].
Participants will remain in a supine position with their legs
elevated (to facilitate venous emptying) for the duration of the
test. A cuff will be placed on the upper thigh of the nonbiopsy
leg (so as not to put pressure on the biopsy site) to act both as
a venous and arterial occlusion cuff while a mercury strain gauge
(sized at ~4 cm less than calf width) is affixed around the largest
part of the gastrocnemius. For resting measures, the thigh cuff
will be inflated to 50 mmHg for 4 to 6 cycles of inflation and
deflation to obtain resting blood flow measures. Resting blood
flow will be recorded as the average of 3 measurements. Peak
hyperemic blood flow will be determined following an ischemic
occlusion (pressure set to 30 mmHg above systolic pressure)
of the thigh for a period of 5 min. Postocclusion blood flow
measurements were obtained every few seconds following cuff
release, with the peak value being recorded as the highest value
achieved.
Vascular stiffness will be assessed by PWV and pulse wave
reflection using applanation tonometry via a SphygmoCor XCEL
system (AtCor Medical, New South Whales, Australia. The
SphygmoCor is a noninvasive diagnostic system that has been
used to provide assessments of both the central blood pressure
and PWV of clinical patients [63]. For the measurement of pulse
wave analysis (PWA), a SphygmoCor arm cuff is placed on the
upper arm, aligning the designated markings with the brachial
artery. The system then measures pulsations recorded at the
brachial artery to produce central aortic pressure waveforms
and predict the following: central systolic pressure, central pulse
pressure, augmentation pressure, and augmentation index. PWV
is measured via a simultaneous comparison of the carotid and
femoral arterial pulses. A thigh cuff will be placed around the
participant’s upper thigh, which acts to measure the femoral
pulse via pulsations, while simultaneously a tonometer will be
used to assess the carotid pulse. Higher pulse wave velocities
from the carotid to femoral arteries indicate higher aortic
stiffness.
Submaximal Echocardiograph Visit
For this visit, participants will again be asked to refrain from
exercise and alcohol for the 24 hours before testing and to
abstain from caffeine and smoking for the 3 hours before testing.
They will be instructed to follow their normal dietary routine
and take their medications. For this visit, participants will
complete a series of 3 discontinuous stages (5-min rest in
between each stage) of exercise on an echo-compatible
recumbent cycle ergometer (Vivid 7 echocardiographic machine,
GE, Milwaukee, Wisconsin). At present, the most common
measure to assess the heart function during exercise is to have
the participant exercise and then capture images immediately
after exercise completion. The design of this cycle places the
participant in an ideal position to capture echocardiograph
images during exercise, allowing for more accurate assessment
of cardiac function during exercise. Three independent
workloads will be chosen based on participant capacity (Stage
1: 5-20 watts, Stage 2: 15-40 watts, and Stage 3: 30-60 watts).
During the exercise test, participants will be fitted with the NIRS
device, PhysioFlow, and electrocardiogram, similar to the one
used during the max CPX. The echocardiograph will provide
measures of CO, stroke volume (SV), mean arterial pressure
(MAP), cardiac power output, left-ventricular end-systolic
elastance, arterial elastance, preload recruitable stroke work,
long-axis contraction and relaxation, mitral flow propagation
velocity, and tricuspid incompetence. All echocardiograph
assessments will be taken by the same tester to control for
intertester variability.
Vastus Lateralis Muscle Biopsy Visit
The biopsy will be performed in a similar fashion to previous
studies by our group on a separate day with at least 48 hours
recovery between other testing visits [64,65]. In brief, the
participant will be placed in a supine position. Following an
injection of local anesthetic into the skin and fascia (1%
Xylocaine), a small incision will be made at the level of the left
vastus lateralis. A muscle sample will be taken (~150-300 mg
wet weight) using a Bergström biopsy needle with manual
suction applied [66]. Once obtained, muscle samples will be
processed; cleaned of excess blood, fat, and connective tissue;
and split into 3 portions. One portion (10-20 mg) will be
immediately immersed in a 5-ml tube containing ~3 ml of
biopsy-preserving solution kept on ice and used for in situ
measurements of mitochondrial respiration. The second portion
(around 20 mg) will be imbedded with Tissue-Tek for the
immunohistochemistry analysis. The samples will be
immediately frozen in liquid nitrogen and stored at −80°C for
subsequent analyses.
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Ethical Considerations
This study has been approved by the Melbourne Health
[HREC/15/MH/166] and Victoria University Ethics Committees.
The trial has been registered in the Australian New Zealand
Clinical Trials Registry [ACTRN12615000906550].
Outcome Measurements
The primary outcome measure will be exercise tolerance
[VO2peak and TTE] during the 2-step CPX test. Secondary
outcomes will include measures at rest and during exercise for
cardiac function (CO, SV, MAP), as well as peripheral tissue
function (lower limb blood flow, endothelial function, PWA,
PWV, mitochondrial function). In addition, measures of plasma
nitrate and nitrite will be recorded for nitrate-nitrite conversion
rate calculations.
Complications and Adverse Events
Although complications and adverse events associated with the
intervention are unlikely, participants will be asked to self-report
any symptoms or adverse events they experience. The only
previously documented side effects are beeturia (red urine) and
red stools [23,67]. Any adverse events noted by the researchers
or participants will be reported in the final manuscript.
Statistical Analysis
The primary endpoint of this pilot study is exercise capacity
(VO2peak and TTE) during the maximal CPX in both the HFpEF
and HFrEF cohorts. A repeated-measures t test will be conducted
to determine the changes in exercise capacity variables in the
2 groups combined. This will be followed by a repeated measure
analysis of variance to determine the time×group effect in
HFpEF and HFrEF patients. Similar analyses will be performed
on the secondary endpoints/variables listed in the Specific Aims.
Post hoc comparisons of change scores for relevant variables
between HFpEF and HFrEF will be performed. Additional
pairwise tests as well as linear regressions between the placebo
and beetroot juice conditions will be used to determine what
physiological factors (mitochondrial efficiency, endothelial
function, tissue perfusion, leg blood flow, CO) contribute to
any potential changes in exercise tolerance in HFpEF versus
HFrEF.
Results
Data collection from this paper is currently underway. Predicted
completion of the recruitment phase is mid-2018.
Discussion
Principal Findings
Heart failure is a chronic, progressive condition that has
deleterious effects on both the central and peripheral function
of the body, resulting in the hallmark symptom of exercise
intolerance. This decrease in aerobic capacity is linked with
lower rates of survival, a higher burden of disability, and
increased rates of hospitalization for patients with CHF and is
a prime target for rehabilitative interventions [4,68]. Thus,
interventions that can acutely improve the tolerability of exercise
for these patients could represent a crucial step forward for
treatment.
The proposed project will be the first to comprehensively
compare the central and peripheral function at rest and during
exercise in both HFpEF and HFrEF patients on and off nitrate
supplementation. This study will also be the first study in CHF
that assesses the effects of nitrate supplementation within the
skeletal muscle tissue (mitochondrial function, capillary density,
and muscle fiber composition). Results from previous trials (in
healthy individuals) have indicated the potential beneficial
impact of nitrate supplementation on mitochondrial function,
but this mechanistic change has yet to be demonstrated in CHF
patients [21].
Limitations
The sample size for this study, although larger than some
comparable trials, is still quite small. However, the crossover
design helps to reduce the potential variability and improve the
possibility of detecting differences between both the placebo
and beetroot juice groups and the HFpEF and HFrEF groups.
The high chronic dose was chosen to maximize the potential
benefits of the supplementation, but the authors note that the
amount is much higher than what would be consumed naturally
in the diet. Finally, although every effort will be made to keep
the supplementation days consistent before each testing visit
between the placebo and beetroot juice rounds, because of
patient and medical team availability, it is not possible to fully
control this aspect. The 5-day loading period before any testing
should help to standardize the dosing days. However, we will
report any difference in dosing days between the 2 treatment
arms.
Conclusions
Our understanding of the potential effects of nitrate
supplementation in patients with CHF is still in its infancy.
Although the initial studies show promise, the studies have been
small and limited in scope to just 1 classification of CHF. This
is the first study to directly compare the effects of inorganic
nitrate supplementation on patients with HFrEF and HFpEF
following an identical protocol to tease out any changes (and/or
differences in changes) in peripheral and central factors. This
is a critical step in advancing our current knowledge of CHF as
a disease as well as the efficacy of nitrate supplementation.
Given the relationship between exercise capacity and mortality
and morbidity, if inorganic nitrate supplementation can improve
exercise tolerance in patients with CHF, it has the potential to
aid in further refining the treatment of patients in this population.
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PWV: pulse wave velocity
SEES: Subjective Exercise Experience Scale
SNS: sympathetic nervous system
SV: stroke volume
TTE: time to exhaustion
VO2peak: peak oxygen consumption
Edited by G Eysenbach; submitted 30.08.17; peer-reviewed by B Piknova; comments to author 30.11.17; revised version received
04.12.17; accepted 05.12.17; published 06.04.18
Please cite as:
Woessner MN, Levinger I, Neil C, Smith C, Allen JD
Effects of Dietary Inorganic Nitrate Supplementation on Exercise Performance in Patients With Heart Failure: Protocol for a
Randomized, Placebo-Controlled, Cross-Over Trial
JMIR Res Protoc 2018;7(4):e86
URL: http://www.researchprotocols.org/2018/4/e86/ 
doi:10.2196/resprot.8865
PMID:29625952
JMIR Res Protoc 2018 | vol. 7 | iss. 4 | e86 | p.11http://www.researchprotocols.org/2018/4/e86/
(page number not for citation purposes)
Woessner et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
©Mary N. Woessner, Itamar Levinger, Christopher Neil, Cassandra Smith, Jason D Allen. Originally published in JMIR Research
Protocols (http://www.researchprotocols.org), 06.04.2018. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The
complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright
and license information must be included.
JMIR Res Protoc 2018 | vol. 7 | iss. 4 | e86 | p.12http://www.researchprotocols.org/2018/4/e86/
(page number not for citation purposes)
Woessner et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
